Compare New Era Energy & Digital Inc. Common Stock (NUAI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New Era Energy & Digital Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? New Era Energy & Digital Inc. Common Stock trades at $3.37 (market cap $518.22M), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 7× New Era Energy & Digital Inc. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while New Era Energy & Digital Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold New Era Energy & Digital Inc. Common Stock for 2 Days and Organon & Co. Common Stock for 0 Days on average.
| NUAI | OGN | |
|---|---|---|
Market Cap | $518.22M | $3.61B |
Volume | 7,267,523 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $8.06 | $13.81 |
52-Week Low | $2.37 | $5.70 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $463.57M | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUAI trades at $4.29, down 1.15% today, with a bearish technical signal despite recent positive news about a 20-year power deal for its Texas data center project. The company shows severe financial stress with negative margins (-5,985.71% net income margin) and consecutive quarterly losses, though analyst consensus remains bullish with a $10.67 price target. Recent institutional interest includes BlackRock's new stake in Q2 2026.
The stock presents high-risk speculation with potential upside if data center development succeeds, but faces substantial execution and funding risks. Current fundamentals are weak, making it suitable only for risk-tolerant investors betting on future project milestones and hyperscaler partnerships.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
